Barclays PLC Infla Rx N.V. Transaction History

Barclays PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.35 - $5.58 $4 - $11	-2 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$2.25 - $3.03 $63 - $84	-28 Reduced 93.33%	2 $0
Q3 2020 Nov 12, 2020	SELL	$3.7 - $5.47 $2,590 - $3,829	-700 Reduced 95.89%	30 $0
Q2 2020 Aug 12, 2020	BUY	$4.59 - $8.96 $2,891 - $5,644	630 Added 630.0%	730 $3,000
Q1 2020 May 13, 2020	SELL	$2.65 - $6.08 $132,235 - $303,392	-49,900 Reduced 99.8%	100 $0

Q3 2019 Nov 14, 2019	SELL	$2.47 - $3.51 $123,500 - $175,500	-50,000 Reduced 50.0%	50,000 $124,000
Q2 2019 Aug 14, 2019	BUY	$3.06 - $51.61 $306,000 - $5.16 Million	100,000 New	100,000 $316,000
Q3 2018 Nov 14, 2018	SELL	$29.34 - $35.0 $11,736 - $14,000	-400 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$27.33 - $41.46 $125,717 - $190,716	-4,600 Reduced 92.0%	400 $13,000
Q1 2018 May 15, 2018	BUY	$20.21 - $32.0 $101,050 - $160,000	5,000 New	5,000 $144,000

13.8M

12.9K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $76.5M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.